Teva Pharmaceutical Industries Limited (TEVA) Taking $109 Million Charge, Ending Cancer Drug Work With CureTech Ltd.
1/31/2013 7:19:00 AM
More...
|
Teva Pharmaceutical Industries Limited (TEVA) Invests Additional $19 Million in CureTech Ltd., Will Finance Up to $50 Million of R&D Program
9/13/2011 8:09:50 AM
More...
|
Teva Pharmaceutical Industries Limited (TEVA) and CureTech Ltd. Announce Positive Phase II Data from CT-011, an Investigational Antibody in Diffuse Large B Cell Lymphoma
5/17/2011 9:23:23 AM
More...
|
CureTech Ltd. Announces Encouraging Phase I Clinical Trial Results In Cancer Patients With Its Monoclonal Antibody CT-011
10/19/2005 5:13:15 PM
More...
|